Powerful BP Efficacy Demonstrated for the Hypertensive Patients You Treat

For Your Goals...
Prompt and Powerful BP Efficacy

Both AVAPRO and AVALIDE provide prompt BP lowering at 2 weeks^12-14
AVALIDE: INCLUSIVE trial demonstrated powerful BP reduction in patients with systolic blood pressure (SBP) uncontrolled on monotherapy¹⁶
AVAPRO: Powerful SBP and diastolic blood pressure (DBP) reductions comparable to one of the most widely prescribed antihypertensive agents, amlodipine, at starting doses¹⁵

In clinical trials with hypertensive patients…
AVAPRO/AVALIDE provided tolerability similar to placebo at every dose

No significant difference from placebo in the incidence of cough (AVAPRO 2.8% vs placebo 2.7%), fatigue
(AVAPRO 4.0% vs placebo 3.0%), and edema
(AVAPRO 2.0% vs placebo 3.0%)
Not associated with an increased incidence of dry cough, as is associated with ACE inhibitor use
Fewer patients discontinued AVAPRO and AVALIDE than placebo
No significant drug interactions between AVAPRO and hydrochlorothiazide, digoxin, warfarin, or nifedipine

Available in a full range of dosage strengths

Read more about dosing for AVAPRO and AVALIDE.

USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AVAPRO or AVALIDE should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

Please see Indications, Important Safety Information and full Prescribing Information.